This review focuses on the recent advances in non-invasive in vivo β-cell imaging and BCM evaluation for type 1 and type 2 diabetes mellitus, especially exendin-based GLP-1R-targeted nuclear medicine techniques. The gene discussed is GLP1R; the disease is diabetes mellitus.